+

US20090186925A1 - Nicotinic acid compositions for treating hyperlipidemia and related methods therefor - Google Patents

Nicotinic acid compositions for treating hyperlipidemia and related methods therefor Download PDF

Info

Publication number
US20090186925A1
US20090186925A1 US12/350,654 US35065409A US2009186925A1 US 20090186925 A1 US20090186925 A1 US 20090186925A1 US 35065409 A US35065409 A US 35065409A US 2009186925 A1 US2009186925 A1 US 2009186925A1
Authority
US
United States
Prior art keywords
nicotinic acid
weight
tablet
parts
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/350,654
Inventor
David J. Bova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29783152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20090186925(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/368,378 external-priority patent/US6080428A/en
Priority claimed from US08/814,974 external-priority patent/US6129930A/en
Application filed by Individual filed Critical Individual
Priority to US12/350,654 priority Critical patent/US20090186925A1/en
Publication of US20090186925A1 publication Critical patent/US20090186925A1/en
Priority to US12/756,288 priority patent/US20110003783A1/en
Priority to US13/406,038 priority patent/US20120157503A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Definitions

  • This invention generally relates to compositions of nicotinic acid useful for treating hyperlipidemia and methods of treating hyperlipidemia employing such compositions. More particularly, the present invention employs a composition of nicotinic acid, derivatives and mixtures thereof, and a swelling agent to form a time release sustaining composition for nocturnal or evening dosing. Specifically, the present invention employs a composition of nicotinic acid and hydroxypropyl methylcellulose to treat hyperlipidemia in a once per day oral dosage form given during the evening hours.
  • Nicotinic acid has been used for many years in the treatment of hyperlipidemia. This compound has long been known to exhibit the beneficial effects of reducing total cholesterol, low density lipoproteins or “LDL cholesterol”, triglycerides and apolipoprotein a (Lp(a)) in the human body, while increasing desirable high density lipoproteins or “HDL cholesterol”.
  • Nicotinic acid has normally been administered three times per day after meals. This dosing regimen is known to provide a very beneficial effect on blood lipids as discussed in Knopp et al; “Contrasting Effects of Unmodified and Time-Release Forms of Niacin on Lipoproteins in Hyperlipidemic Subjects Clues to Mechanism of Action of Niacin”; Metabolism 34/7, 1985, page 647.
  • the chief advantage of this profile is the ability of nicotinic acid to decrease total cholesterol, LDL cholesterol, triglycerides and Lp(a) while increasing HDL particles. While such a regimen does produce beneficial effects, cutaneous flushing and the like still often occurs in the hyperlipidemics to whom the compound is administered.
  • Sustained release formulations are designed to slowly release the compound from the tablet or capsule. The slow drug release reduces and prolongs blood levels of drug and thus minimizes the side effects.
  • Sustained release formulations of niacin have been developed, such as NICOBIDTM capsules (Rhone-Poulenc Rorer), ENDUR-ACINTM (Innovite Corporation) and U.S. Pat. No. 5,126,145 which describes a sustained release niacin formulation containing two different types of hydroxypropyl methylcellulose and a hydrophobic component.
  • sustained release niacin products do not have the same advantageous lipid altering effects as immediate release niacin, and in fact often have a worse side effect profile compared to the immediate release product.
  • the major disadvantage of the sustained release formulations is the significantly lower reduction in triglycerides ( ⁇ 2% for the sustained release versus ⁇ 38% for the immediate release) and lower increase in HDL cholesterol, represented as HDL 2 particles which are known by the an to be most beneficial ( ⁇ 5% for the sustained release versus +37% for the immediate release).
  • sustained release niacin formulations have been noted as causing greater incidences of liver toxicity as described in Henken et al (Am J Med 91:1991 1991) and Dalton et al (Am J Med 93: 102 1992). There is also great concern regarding the potential of these formulations in disrupting glucose metabolism and uric acid levels.
  • the present invention alleviates and overcomes certain of the above-identified problems and shortcomings of the present state of nicotinic acid therapy through the discovery of novel nicotinic acid formulations and methods of treatment.
  • the present invention provides an improved antihyperlipidemia composition of the oral type employing an effective antihyperlipidemic amount of nicotinic acid, wherein the improvement comprises compounding the nicotinic acid with from about 5% to about 50% parts by weight of hydroxypropyl methylcellulose per hundred parts by weight of tablet or formulation.
  • the present invention also provides an orally administered antihyperlipidemia composition which comprises from about 30% to about 90% parts by weight of nicotinic acid; and, from about 5% to about 50% parts by weight of hydroxypropyl methylcellulose.
  • the present invention also includes a method of treating hyperlipidemia in a hyperlipidemic.
  • the method comprises the steps of forming a composition which comprises an effective antihyperlipidemic amount of nicotinic acid and an amount of excipients to provide sustained release of drug.
  • the method also includes the step of orally administering the composition to the hyperlipidemic nocturnally.
  • a method of treating hyperlipidemia in a hyperlipidemic according to the invention comprises dosing the hyperlipidemic with an effective antihyperlipidemic amount of nicotinic acid or compound metabolized to nicotinic acid by the body.
  • the dose is given once per day in the evening or at night, combined with a pharmaceutically acceptable carrier to produce a significant reduction in total and LDL cholesterol, as well as a significant reduction in triglycerides and Lp(a), with a significant increase in HDL cholesterol.
  • the present invention employs nicotinic acid or a compound other than nicotinic acid itself which the body metabolizes into nicotinic acid, thus producing the same effect as described herein.
  • the other compounds specifically include, but are not limited to the following: nicotinyl alcohol tartrate, d-glucitol hexanicotinate, aluminum nicotinate, niceritrol and d,1-alpha-tocopheryl nicotinate. Each such compound will be collectively referred to hereinbelow by “nicotinic acid.”
  • nicotinic acid has been employed in the past for the treatment of hyperlipidemia, which condition is characterized by the presence of excess fats such as cholesterol and triglycerides, in the blood stream.
  • a sustained release composition of nicotinic acid is prepared as an example.
  • sustained release it is understood to mean a composition which when orally administered to a patient to be treated, the active ingredient will be released for absorption into the blood stream over a period of time.
  • the specific sustained release composition according to the present invention employs an effective antihyperlipidemic amount of nicotinic acid.
  • effective antihyperlipidemic amount it is understood to mean an amount which when orally administered to a patient to be treated, will have a beneficial effect upon the physiology of the patient, to include at least some lowering of total cholesterol, LDL cholesterol, triglycerides and Lp(a) and at least some increase in HDL cholesterol in the patient's blood stream.
  • An exemplary effective antihyperlipidemic amount of nicotinic acid would be from about 250 mgs to about 3000 mgs of nicotinic acid to be administered according to the invention as will be more fully described hereinbelow. This amount will vary dependent upon a number of variables, including the psychological needs of the patient to be treated.
  • a swelling agent which is compounded with the nicotinic acid, such that when the composition is orally administered to the patient, the swelling agent will swell over time in the patient's gastrointestinal tract and release the active nicotinic acid, or a compound which produces nicotinic acid into the gastrointestinal system for absorption into the blood stream, over a period of time.
  • swelling agents and amounts thereof may be preselected in order to control the time release of the active ingredient.
  • Such swelling agents include, but are not limited to, polymers such as sodium carboxymethylcellulose and ethylcellulose and waxes such as bees wax and natural materials such as gums and gelatins or mixtures of any of the above. Because the amount of the swelling agent will vary depending upon the nature of the agent, the time release needs of the patient and the like, it is preferred to employ amounts of the agent which will accomplish the objects of the invention.
  • An exemplary and preferred swelling agent is hydroxypropyl methylcellulose, in an amount ranging from about 5% to about 50% parts by weight per 100 parts by weight of tablet or formulation.
  • the preferred example will ensure a sustained time release over a period of approximately 4-24 hours as demonstrated by in vitro dissolution techniques known to the art.
  • a binder may also be employed in the present compositions. While any known binding material is useful in the present invention, it is preferred to employ a material such as one or more of a group of polymers having the repeating unit of 1-ethenyl-2-pyrrolidinone. These polymers generally have molecular weights of between about. 10,000 and 700,000 and are also known as “povidone”.
  • Amounts of the binder material will of course, vary depending upon the nature of the binder and the amount of other ingredients of the composition.
  • An exemplary amount of povidone in the present compositions would be from about 1% to about 5% by weight of povidone per 100 parts by weight of the total formulation.
  • Processing aids such as lubricants, including stearic acid, may also be employed, as is known in the art.
  • An exemplary amount of stearic acid in the present compositions would be from about 0.5% to about 2.0% by weight per 100 parts by weight of tablet or formulation.
  • compositions and method of the present invention over known antihyperlipidemia compositions and methods heretofore known in the art, a number of substantially identical composition were prepared according to the disclosure hereinabove.
  • the composition ingredients and amounts are listed in TABLE IA hereinbelow.
  • NIASPAN® once-daily tablets in accordance with the present invention utilize a hydrophilic matrix controlled drug delivery system.
  • This is a dynamic system composed of polymer wetting, polymer hydration and polymer disintegration/dissolution.
  • the mechanism by which drug release is controlled depends on, for example, initial polymer wetting, expansion of the gel layer, tablet erosion and niacin solubility.
  • the hydrophilic polymer starts to partially hydrate, forming a gel layer.
  • drug diffuses out of the gel layer.
  • the controlled release from this matrix delivery system can be modified depending on the type and molecular weight of hydrophilic polymer used.
  • a NIASPAN® formulation consists of Niacin, METHOCEL® E10M Premium, Povidone K90 and HYSTRENE® 5016 (stearic acid). METHOCEL® E10M Premium is utilized as a controlled-release agent in the NIASPAN® formulation. METHOCEL® is a partly O-methylated and O-(2-hydroxypropylated) cellulose and is available in several grades which vary in terms of viscosity and degree of substitution. METHOCEL® is manufactured by Dow Chemical.
  • Povidone K90 is employed as a granulating/binding agent in a NIASPAN® formulation.
  • Povidone is a synthetic polymer consisting of linear 1-vinyl-2-pyrrolidone groups, the degree of polymerization of which results in polymers of various molecular weights, or as indicated above. It is characterized by its viscosity in aqueous solution, relative to that of water, expressed as a K-value, ranging from 10-120.
  • Povidone K90 has an approximate molecular weight of 1,000,000.
  • Povidone is a hygroscopic, water soluble material.
  • Povidone K90 present in a NIASPAN® formulation is manufactured by ISP (International Specialty Products).
  • HYSTRENE® 5016 is utilized as an external lubricant in the NIASPAN® formulation.
  • HYSTRENE® 5016 is a mixture of stearic acid and palmitic acid. The content of stearic acid is not less than about 40.0% and the sum of the two acids is not less than about 90.0%.
  • HYSTRENE® 5016 is manufactured by Witco. Refer to Table IB for NIASPAN® formulation details.
  • each formulation is identical.
  • the major component of each formulation is a granulated mixture of Niacin, METHOCEL® E10M and Povidone K90.
  • the granulation process improves compression properties.
  • NIASPAN® formulations are presented in white caplet shape tablets. Caplet dimensions differ with respect to product strength. The 375 mg and 500 mg NIASPAN® tablets are compressed with tooling measuring approximately 0.687′′ in length ⁇ 0.281′′ by width. The length and width of the 750 mg and 1000 mg tooling measures approximately 0.750′′ ⁇ 0.320′′. Target tablet weight and hardness dictate thickness across the four NIASPAN® products. The production of the NIASPAN® tablets will now be described generally as set forth below.
  • NIASPAN® granulation raw materials are dispensed and granulated in a high shear granulator.
  • the wet granules are sieved into a fluid bed drier and are dried. When the drying process is complete, the granules are milled. Milling ensures uniform particle size distribution throughout the NIASPAN® granulation.
  • a NIASPAN® tablet blend is manufactured by blending the NIASPAN® granulation, extragranular METHOCEL® E10M and HYSTRENE® 5016.
  • the quantities of each NIASPAN® tablet blend component will depend on the particular NIASPAN® dose being manufactured (refer to Table IB).
  • a NIASPAN® tablet blend is compressed to form NIASPAN® tablets.
  • NIASPAN® tablet physical properties will vary depending on the particular NIASPAN® dose being manufactured.
  • NIASPAN® tablets Production of NIASPAN® tablets will now be discussed in greater detail.
  • the initial stage of manufacturing is the same for all four tablet strengths of NIASPAN® (375, 500, 750, and 1000 mg).
  • One batch of NIASPAN® granulation is comprised of four individual 40.0 kg units of granulation which are processed separately, but under like conditions. The four individual granulations are sampled and tested individually and subsequently released for blending.
  • the base granulation is not strength specific and may be used to manufacture any tablet strength of NIASPAN®.
  • Raw materials are quantatively dispensed into appropriately labeled double polyethylene-lined containers using calibrated scales.
  • Purified Water, USP is dispensed into an appropriate vessel from which it is later pumped during the wet-massing operation.
  • a Littleford FM130 granulator is charged with approximately one half of the Niacin, USP required for the process unit ( ⁇ 17.4 kg) followed by about 4.00 kg of METHOCEL®, USP E10M Premium CR Grade; about 1.20 kg of Povidone, USP; and the balance of the Niacin, SP ( ⁇ 17.40 kg).
  • the powder bed is dry mixed in the Littleford FM130 granulator, with choppers on, for approximately 1 minute.
  • about 12.0 ⁇ 0.05 kg of Purified Water, USP are sprayed onto the powder bed at a rate of about 2.40 ⁇ 0.24 kg/minute.
  • the unit is granulated for about 5 minutes.
  • the granulated unit is discharged into double polyethylene-lined containers and then manually loaded into a Glatt bowl while being passed through a #4 mesh screen.
  • the Glatt bowl is loaded into a Glatt TFO-60 fluid-bed drier with an inlet air temperature setting of about 70° C. ⁇ 5° C.
  • the unit is dried until a moisture level of ⁇ 1.0% is obtained as determined using a COMPUTRACT® Moisture Analyzer, model MA5A.
  • the dried granulation is discharged into appropriately labeled, double polyethylene-lined drums and reconciled.
  • the dried and reconciled granulation is passed through a KEMUTEC BETAGRIND® mill equipped with a 1.5 mm screen and running at approximately 1500 RPM.
  • the milled granulation is collected into appropriately labeled, double polyethylene-lined drums and reconciled.
  • the milled granulation is sampled and tested by Quality Control and released prior to further processing.
  • the released granulation units are charged to a Patterson-Kelley 20 ft 3 V-blender after which they are blended together for about 10 ⁇ 1 minutes and then discharged to appropriately labeled, double polyethylene-lined containers.
  • NIASPAN® tablets are formulated from a common granulation which is blended with appropriate quantities of METHOCEL®, USP E10M Premium CR Grade and Stearic Acid, NF to achieve the final dosage formulation.
  • Tables IA and IB describe the formulation for each NIASPAN® tablet strength, 375 mg, 500 mg, 750 mg, and 1000 mg, respectively.
  • the increases in HDL cholesterol obtained from dosing the sustained release formulation during the evening or at night were +23.0% for one group and +25.3% for the other group. Dosing during the evening therefore provides reduction in LDL cholesterol plus significant decreases in triglycerides and increases in HDL cholesterol with once-a-day dosing.
  • Groups A and B were also tested for liver enzymes (AST, ALT and Alkaline Phosphatase), uric acid and fasting glucose levels at the start of the study described hereinabove (to form a baseline) and at two, four and eight week intervals. The results of these tests are listed in TABLES III-VII hereinbelow.
  • Range GROUP A 1 28 29 25 24 0-50 2 24 25 24 26 0-50 3 17 18 22 21 0-50 4 14 16 15 17 0-50 5 22 NA 32 52 0-50 6 21 17 17 14 0-50 7 17 17 14 18 0-50 8 20 21 22 22 0-50 9 16 16 17 20 0-50 10 18 21 21 25 0-50 11 21 21 22 21 0-50 GROUP B 1 23 25 38 33 0-50 2 20 20 21 21 0-50 3 15 20 18 19 0-50 4 25 22 25 26 0-50 5 23 21 17 18 0-50 6 PATIENT WITHDREW DUE TO FLUSHING 7 21 18 18 19 0-50 8 18 19 18 19 0-50 9 15 16 18 15 0-50 10 16 15 19 28 0-50 11 20 22 24 28 0-50 12 23 25 28 22 0-50 13 20 15 20 19 0-50 14 18 25 20 18 0-50 Combined Mean 19.8 20.4 20.8 21.1 Change From +3.0% +5.1% +6.6% Baseline Level of Significance: p 0.4141
  • Range GROUP A 1 32 28 39 30 0-55 2 24 25 23 26 0-55 3 18 23 30 30 0-55 4 7 13 14 14 0-55 5 14 NA 43 46 0-55 6 22 11 14 10 0-55 7 9 7 11 7 0-55 8 16 18 23 21 0-55 9 14 17 20 14 0-55 10 14 15 17 19 0-55 11 18 18 20 16 0-55 GROUP B 1 16 17 27 29 0-55 2 16 14 15 22 0-55 3 13 21 13 16 0-55 4 23 20 26 17 0-55 5 21 23 17 15 0-55 6 PATIENT WITHDREW DUE TO FLUSHING 7 21 16 18 21 0-55 8 18 20 17 18 0-55 9 11 5 11 8 0-55 10 8 10 14 17 0-55 11 17 12 18 16 0-55 12 14 18 20 16 0-55 13 14 NA 11 10 0-55 14 23 23 19 19 0-55 Combined Mean 17.7 17.5 19.3 18.2 Change From ⁇ 1.1% 9.0% +2.8% Baseline Level of Significance: p 0.3424
  • Range GROUP A 1 114 122 123 110 70-115 2 101 105 107 101 80-125 3 99 98 109 103 70-115 4 100 118 94 94 80-125 5 89 NA 82 103 80-125 6 97 103 94 107 70-115 7 85 107 100 94 80-125 8 98 107 103 101 80-125 9 97 97 100 110 80-125 10 94 101 111 97 70-115 11 102 103 95 95 80-125 GROUP B 1 101 97 83 99 70-115 2 90 95 96 89 80-125 3 96 98 95 97 70-115 4 116 139 113 125 80-125 5 88 92 91 95 70-115 6 PATIENT WITHDREW DUE TO FLUSHING 7 106 114 118 117 70-115 8 95 106 106 108 70-115 9 81 92 84 92 70-115 10 108 117 122 105 70-115 11 85 106 106 108 70-115
  • compositions and method of the present invention are highly effective in controlling hyperlipidemia in hyperlipidemics, by reducing the levels of LDL cholesterol, triglyceride and Lp(a) while increasing HDL 2 cholesterol levels.
  • the present invention is also demonstrated not to cause elevations in liver function tests, uric acid or glucose levels for the hyperlipidemics.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyper lipidemic having a substantially periodic physiological loss of consciousness, includes the steps of forming a composition having an effective antihyperlipidemic amount of nicotinic acid and a time release sustaining amount of a swelling agent. The method also includes the step of orally administering the composition to the hyperlipidemic once per day “nocturnally,” that is in the evening or at night.

Description

    RELATED PATENT APPLICATIONS
  • This application for U.S. patent is a U.S.C., Title 35, §111(a) application which is a continuation of U.S. Ser. No. 11/757,967 filed on Jun. 4, 2007 which is a continuation of U.S. Ser. No. 10/444,145 filed on May 23, 2003, which is a continuation of U.S. Ser. No. 09/478,325 filed on Jan. 6, 2000, which is a continuation-in-part of U.S. Ser. No. 08/368,378, filed on Jan. 14, 1995, now U.S. Pat. No. 6,080,428, which is a continuation-in-part of U.S. Ser. No. 08/124,392, filed on Sep. 20, 1993, which is now abandoned.
    • FIELD OF THE INVENTION
  • This invention generally relates to compositions of nicotinic acid useful for treating hyperlipidemia and methods of treating hyperlipidemia employing such compositions. More particularly, the present invention employs a composition of nicotinic acid, derivatives and mixtures thereof, and a swelling agent to form a time release sustaining composition for nocturnal or evening dosing. Specifically, the present invention employs a composition of nicotinic acid and hydroxypropyl methylcellulose to treat hyperlipidemia in a once per day oral dosage form given during the evening hours.
    • BACKGROUND
  • Nicotinic acid has been used for many years in the treatment of hyperlipidemia. This compound has long been known to exhibit the beneficial effects of reducing total cholesterol, low density lipoproteins or “LDL cholesterol”, triglycerides and apolipoprotein a (Lp(a)) in the human body, while increasing desirable high density lipoproteins or “HDL cholesterol”.
  • Nicotinic acid has normally been administered three times per day after meals. This dosing regimen is known to provide a very beneficial effect on blood lipids as discussed in Knopp et al; “Contrasting Effects of Unmodified and Time-Release Forms of Niacin on Lipoproteins in Hyperlipidemic Subjects Clues to Mechanism of Action of Niacin”; Metabolism 34/7, 1985, page 647. The chief advantage of this profile is the ability of nicotinic acid to decrease total cholesterol, LDL cholesterol, triglycerides and Lp(a) while increasing HDL particles. While such a regimen does produce beneficial effects, cutaneous flushing and the like still often occurs in the hyperlipidemics to whom the compound is administered.
  • In order to avoid or reduce the cutaneous flushing, a number of materials have been suggested for administration with an effective antihyperlipidemic amount of nicotinic acid, including guar gum in U.S. Pat. No. 4,965,252, and mineral salts as disclosed in U.S. Pat. No. 5,023,245; or inorganic magnesium salts as reported in U.S. Pat. No. 4,911,917. These materials have been reported to avoid or reduce the cutaneous flushing side effect commonly associated with nicotinic acid treatment.
  • Another method of avoiding or reducing the side effects associated with immediate release niacin is the use of sustained release formulations. Sustained release formulations are designed to slowly release the compound from the tablet or capsule. The slow drug release reduces and prolongs blood levels of drug and thus minimizes the side effects. Sustained release formulations of niacin have been developed, such as NICOBID™ capsules (Rhone-Poulenc Rorer), ENDUR-ACIN™ (Innovite Corporation) and U.S. Pat. No. 5,126,145 which describes a sustained release niacin formulation containing two different types of hydroxypropyl methylcellulose and a hydrophobic component.
  • Studies in hyperlipidemic patients have been conducted with a number of sustained release niacin products. These studies have demonstrated that the sustained release products do not have the same advantageous lipid altering effects as immediate release niacin, and in fact often have a worse side effect profile compared to the immediate release product. The major disadvantage of the sustained release formulations, as can be seen in Knopp et al., 1985, is the significantly lower reduction in triglycerides (−2% for the sustained release versus −38% for the immediate release) and lower increase in HDL cholesterol, represented as HDL2 particles which are known by the an to be most beneficial (−5% for the sustained release versus +37% for the immediate release).
  • Additionally, sustained release niacin formulations have been noted as causing greater incidences of liver toxicity as described in Henken et al (Am J Med 91:1991 1991) and Dalton et al (Am J Med 93: 102 1992). There is also great concern regarding the potential of these formulations in disrupting glucose metabolism and uric acid levels.
  • In a recent edition of the JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (JAMA), an article appeared which presented research results investigating the liver toxicity problems associated with a sustained release form of nicotinic acid. “A Comparison of the Efficacy and Toxic Effects of Sustained-vs. Immediate-Release Niacin in Hypercholesterolemic Patients”, McKenney et al., JAMA, Vol. 271, No. 9, Mar. 2, 1994, page 672. The article presented a study of twenty-three patients. Of that number, 18 or 78 percent were forced to withdraw because liver function tests (LFTs) increased indicating potential liver damage. The conclusion of the authors of that article was that the sustained release form of niacin “should be restricted from use.”
  • A similar conclusion was reached in an article authored by representatives of the Food and Drug Administration and entitled “Hepatic Toxicity of Unmodified and Time-Release Preparations of Niacin”, Rader, et al., THE AMERICAN JOURNAL OF MEDICINE, Vol. 92, January 1992, page 77. Because of these studies and similar conclusions drawn by other health care professionals, the sustained release forms of niacin have experienced limited utilization.
  • Therefore, it can be seen from the scientific literature that there is a need for development of a sustained release niacin formulation and a method of delivering said formulation which would provide hyperlipidemic patients with “balanced lipid alteration”, i.e. reductions in total cholesterol, LDL cholesterol, triglycerides and Lp(a) as well as increases in HDL particles, with an acceptable safety profile, especially as regards liver toxicity and effects on glucose metabolism and uric acid levels.
    • SUMMARY OF THE INVENTION
  • In brief, the present invention alleviates and overcomes certain of the above-identified problems and shortcomings of the present state of nicotinic acid therapy through the discovery of novel nicotinic acid formulations and methods of treatment.
  • It is therefore an object of the present invention to provide a composition of nicotinic acid or any compound which is metabolized by the body to form nicotinic acid for treating hyperlipidemia.
  • It is another object of the present invention to provide a composition as above, which has a time release sustaining characteristic.
  • It is yet another object of the present invention to provide a method for employing a composition as above, for treating hyperlipidemia, which results in little or no liver damage.
  • At least one or more of the foregoing objects, together with the advantages thereof over the known art relating to the treatment of hyperlipidemia, which shall become apparent from the specification which follows, are accomplished by the invention as hereinafter described and claimed.
  • In general the present invention provides an improved antihyperlipidemia composition of the oral type employing an effective antihyperlipidemic amount of nicotinic acid, wherein the improvement comprises compounding the nicotinic acid with from about 5% to about 50% parts by weight of hydroxypropyl methylcellulose per hundred parts by weight of tablet or formulation.
  • The present invention also provides an orally administered antihyperlipidemia composition which comprises from about 30% to about 90% parts by weight of nicotinic acid; and, from about 5% to about 50% parts by weight of hydroxypropyl methylcellulose.
  • The present invention also includes a method of treating hyperlipidemia in a hyperlipidemic. The method comprises the steps of forming a composition which comprises an effective antihyperlipidemic amount of nicotinic acid and an amount of excipients to provide sustained release of drug. The method also includes the step of orally administering the composition to the hyperlipidemic nocturnally.
  • A method of treating hyperlipidemia in a hyperlipidemic according to the invention comprises dosing the hyperlipidemic with an effective antihyperlipidemic amount of nicotinic acid or compound metabolized to nicotinic acid by the body. The dose is given once per day in the evening or at night, combined with a pharmaceutically acceptable carrier to produce a significant reduction in total and LDL cholesterol, as well as a significant reduction in triglycerides and Lp(a), with a significant increase in HDL cholesterol.
  • The above features and advantages of the present invention will be better understood with reference to the following detailed description and examples. It should also be understood that the particular methods and formulations illustrating the present invention are exemplary only and not to be regarded as limitations of the present invention.
    • DETAILED DESCRIPTION OF THE INVENTION
  • By way of illustrating and providing a more complete appreciation of the present invention and many of the attendant advantages thereof, the following detailed description and examples are given concerning the novel methods and formulations.
  • The present invention employs nicotinic acid or a compound other than nicotinic acid itself which the body metabolizes into nicotinic acid, thus producing the same effect as described herein. The other compounds specifically include, but are not limited to the following: nicotinyl alcohol tartrate, d-glucitol hexanicotinate, aluminum nicotinate, niceritrol and d,1-alpha-tocopheryl nicotinate. Each such compound will be collectively referred to hereinbelow by “nicotinic acid.”
  • As stated hereinabove, nicotinic acid has been employed in the past for the treatment of hyperlipidemia, which condition is characterized by the presence of excess fats such as cholesterol and triglycerides, in the blood stream. According to the present invention, a sustained release composition of nicotinic acid is prepared as an example. By “sustained release” it is understood to mean a composition which when orally administered to a patient to be treated, the active ingredient will be released for absorption into the blood stream over a period of time. For example, it is preferred that in a dosage of about 1500 milligrams (hereinafter “mgs”) of nicotinic acid, approximately 100 percent of the nicotinic acid will be released to the blood stream in about 4 to about 24 hours.
  • The specific sustained release composition according to the present invention employs an effective antihyperlipidemic amount of nicotinic acid. By “effective antihyperlipidemic amount” it is understood to mean an amount which when orally administered to a patient to be treated, will have a beneficial effect upon the physiology of the patient, to include at least some lowering of total cholesterol, LDL cholesterol, triglycerides and Lp(a) and at least some increase in HDL cholesterol in the patient's blood stream. An exemplary effective antihyperlipidemic amount of nicotinic acid would be from about 250 mgs to about 3000 mgs of nicotinic acid to be administered according to the invention as will be more fully described hereinbelow. This amount will vary dependent upon a number of variables, including the psychological needs of the patient to be treated.
  • Preferably, there is also included in the sustained release composition according to the present invention, a swelling agent which is compounded with the nicotinic acid, such that when the composition is orally administered to the patient, the swelling agent will swell over time in the patient's gastrointestinal tract and release the active nicotinic acid, or a compound which produces nicotinic acid into the gastrointestinal system for absorption into the blood stream, over a period of time. As is known in the art, such swelling agents and amounts thereof, may be preselected in order to control the time release of the active ingredient. Such swelling agents include, but are not limited to, polymers such as sodium carboxymethylcellulose and ethylcellulose and waxes such as bees wax and natural materials such as gums and gelatins or mixtures of any of the above. Because the amount of the swelling agent will vary depending upon the nature of the agent, the time release needs of the patient and the like, it is preferred to employ amounts of the agent which will accomplish the objects of the invention.
  • An exemplary and preferred swelling agent is hydroxypropyl methylcellulose, in an amount ranging from about 5% to about 50% parts by weight per 100 parts by weight of tablet or formulation. The preferred example will ensure a sustained time release over a period of approximately 4-24 hours as demonstrated by in vitro dissolution techniques known to the art.
  • A binder may also be employed in the present compositions. While any known binding material is useful in the present invention, it is preferred to employ a material such as one or more of a group of polymers having the repeating unit of 1-ethenyl-2-pyrrolidinone. These polymers generally have molecular weights of between about. 10,000 and 700,000 and are also known as “povidone”.
  • Amounts of the binder material will of course, vary depending upon the nature of the binder and the amount of other ingredients of the composition. An exemplary amount of povidone in the present compositions would be from about 1% to about 5% by weight of povidone per 100 parts by weight of the total formulation.
  • Processing aids such as lubricants, including stearic acid, may also be employed, as is known in the art. An exemplary amount of stearic acid in the present compositions would be from about 0.5% to about 2.0% by weight per 100 parts by weight of tablet or formulation.
  • Examples of various embodiments of the present invention will now be further illustrated with reference to the following examples.
  • General Experimental
  • In order to demonstrate the effectiveness of the compositions and method of the present invention over known antihyperlipidemia compositions and methods heretofore known in the art, a number of substantially identical composition were prepared according to the disclosure hereinabove. The composition ingredients and amounts are listed in TABLE IA hereinbelow.
  • TABLE IA
    Test Tablet Composition
    Ingredient 375 mg 500 mg 750 mg
    Nicotinic Acid 375.0 500.0 750.0
    Hyroxypropyl methylcellulose 188.7 203.0 204.7
    Povidone 12.9 17.2 25.9
    Stearic Acid 5.8 7.3 9.9
    TOTAL 582.4 mg 727.5 mg 990.5 mg
  • The ingredients were compounded together to form a tablet. More specifically, NIASPAN® once-daily tablets in accordance with the present invention utilize a hydrophilic matrix controlled drug delivery system. This is a dynamic system composed of polymer wetting, polymer hydration and polymer disintegration/dissolution. The mechanism by which drug release is controlled depends on, for example, initial polymer wetting, expansion of the gel layer, tablet erosion and niacin solubility. After initial wetting, the hydrophilic polymer starts to partially hydrate, forming a gel layer. As water permeates into the tablet increasing the thickness of the gel layer, drug diffuses out of the gel layer. As the outer layer of the tablet becomes fully hydrated it erodes. It is believed that this erosion results in additional drug release. The controlled release from this matrix delivery system can be modified depending on the type and molecular weight of hydrophilic polymer used.
  • A NIASPAN® formulation consists of Niacin, METHOCEL® E10M Premium, Povidone K90 and HYSTRENE® 5016 (stearic acid). METHOCEL® E10M Premium is utilized as a controlled-release agent in the NIASPAN® formulation. METHOCEL® is a partly O-methylated and O-(2-hydroxypropylated) cellulose and is available in several grades which vary in terms of viscosity and degree of substitution. METHOCEL® is manufactured by Dow Chemical.
  • Povidone K90 is employed as a granulating/binding agent in a NIASPAN® formulation. Povidone is a synthetic polymer consisting of linear 1-vinyl-2-pyrrolidone groups, the degree of polymerization of which results in polymers of various molecular weights, or as indicated above. It is characterized by its viscosity in aqueous solution, relative to that of water, expressed as a K-value, ranging from 10-120. Povidone K90 has an approximate molecular weight of 1,000,000. Povidone is a hygroscopic, water soluble material. Povidone K90 present in a NIASPAN® formulation is manufactured by ISP (International Specialty Products). HYSTRENE® 5016 is utilized as an external lubricant in the NIASPAN® formulation. HYSTRENE® 5016 is a mixture of stearic acid and palmitic acid. The content of stearic acid is not less than about 40.0% and the sum of the two acids is not less than about 90.0%. HYSTRENE® 5016 is manufactured by Witco. Refer to Table IB for NIASPAN® formulation details.
  • Qualitatively, the four tablet strength formulations are identical. The major component of each formulation is a granulated mixture of Niacin, METHOCEL® E10M and Povidone K90. The granulation process improves compression properties.
  • TABLE IB
    375 mg 500 mg 750 mg 1000 mg
    NIASPAN ® Product Tablets Tablets Tablets Tablets
    Formulation, %/Tablet
    Niacin 64.4 70.5 77.4 83.1
    METHOCEL ® E10M 7.4 8.1 8.9 9.5
    Premium (Intragranular) 2.2 2.4 2.7 2.9
    Povidone K90
    METHOCEL ® E10M 25.0 18.0 10.0 3.5
    Premium (Extragranular)
    HYSTRENE ® 5016 (Stearic 1.0 1.0 1.0 1.0
    Acid)
    Tablet weight, mg 582.5 709.5 968.6 1203.6
  • NIASPAN® formulations are presented in white caplet shape tablets. Caplet dimensions differ with respect to product strength. The 375 mg and 500 mg NIASPAN® tablets are compressed with tooling measuring approximately 0.687″ in length×0.281″ by width. The length and width of the 750 mg and 1000 mg tooling measures approximately 0.750″×0.320″. Target tablet weight and hardness dictate thickness across the four NIASPAN® products. The production of the NIASPAN® tablets will now be described generally as set forth below.
  • NIASPAN® Granulation Process Description
  • NIASPAN® granulation raw materials are dispensed and granulated in a high shear granulator. The wet granules are sieved into a fluid bed drier and are dried. When the drying process is complete, the granules are milled. Milling ensures uniform particle size distribution throughout the NIASPAN® granulation.
  • NIASPAN® Tablet Process Description
  • A NIASPAN® tablet blend is manufactured by blending the NIASPAN® granulation, extragranular METHOCEL® E10M and HYSTRENE® 5016. The quantities of each NIASPAN® tablet blend component will depend on the particular NIASPAN® dose being manufactured (refer to Table IB). A NIASPAN® tablet blend is compressed to form NIASPAN® tablets. NIASPAN® tablet physical properties will vary depending on the particular NIASPAN® dose being manufactured.
  • Production of NIASPAN® tablets will now be discussed in greater detail. The initial stage of manufacturing is the same for all four tablet strengths of NIASPAN® (375, 500, 750, and 1000 mg). One batch of NIASPAN® granulation is comprised of four individual 40.0 kg units of granulation which are processed separately, but under like conditions. The four individual granulations are sampled and tested individually and subsequently released for blending. The base granulation is not strength specific and may be used to manufacture any tablet strength of NIASPAN®.
  • The ingredients in the base granulation are set forth in Table IC below:
  • TABLE IC
    Quantity per % per Quantity
    kilogram kilogram per
    granulation granulation 160.00 kg
    Component Function (kg) (%) batch (kg)
    Niacin USP Drug 0.87 87.00 139.20
    Substance
    Povidone USP Binder 0.03 3.00 4.80
    METHOCEL ® Controlled- 0.10 10.00 16.00
    USP, E10M Release
    Premium CR Agent
    Grade
    Purified Water, Granulation 0.00* 0.00* 48.00
    USP* Reagent
    Total 160.00
    *Purified Water, USP is used as a granulation reagent and does not appear in the finished granulation.
  • Raw materials are quantatively dispensed into appropriately labeled double polyethylene-lined containers using calibrated scales. Purified Water, USP is dispensed into an appropriate vessel from which it is later pumped during the wet-massing operation.
  • A Littleford FM130 granulator is charged with approximately one half of the Niacin, USP required for the process unit (˜17.4 kg) followed by about 4.00 kg of METHOCEL®, USP E10M Premium CR Grade; about 1.20 kg of Povidone, USP; and the balance of the Niacin, SP (˜17.40 kg). The powder bed is dry mixed in the Littleford FM130 granulator, with choppers on, for approximately 1 minute. At the completion of the 1-minute pre-mix cycle, about 12.0±0.05 kg of Purified Water, USP are sprayed onto the powder bed at a rate of about 2.40±0.24 kg/minute. Immediately following the addition of the Purified Water, USP, the unit is granulated for about 5 minutes.
  • The granulated unit is discharged into double polyethylene-lined containers and then manually loaded into a Glatt bowl while being passed through a #4 mesh screen. The Glatt bowl is loaded into a Glatt TFO-60 fluid-bed drier with an inlet air temperature setting of about 70° C.±5° C. The unit is dried until a moisture level of ≦1.0% is obtained as determined using a COMPUTRACT® Moisture Analyzer, model MA5A. The dried granulation is discharged into appropriately labeled, double polyethylene-lined drums and reconciled.
  • The dried and reconciled granulation is passed through a KEMUTEC BETAGRIND® mill equipped with a 1.5 mm screen and running at approximately 1500 RPM. The milled granulation is collected into appropriately labeled, double polyethylene-lined drums and reconciled. The milled granulation is sampled and tested by Quality Control and released prior to further processing.
  • The released granulation units are charged to a Patterson-Kelley 20 ft3 V-blender after which they are blended together for about 10±1 minutes and then discharged to appropriately labeled, double polyethylene-lined containers.
  • As stated above, NIASPAN® tablets are formulated from a common granulation which is blended with appropriate quantities of METHOCEL®, USP E10M Premium CR Grade and Stearic Acid, NF to achieve the final dosage formulation. Tables IA and IB describe the formulation for each NIASPAN® tablet strength, 375 mg, 500 mg, 750 mg, and 1000 mg, respectively.
  • Two study groups consisting of eleven and fourteen patients each were formed. Blood samples were taken from the patients, and tested for total cholesterol, LDL cholesterol, triglycerides and HDL cholesterol to establish baseline levels from which fluctuations in these lipids could be compared. The patients were then placed upon a regimen of the above discussed tablets, totaling approximately 1500 mg of nicotinic acid, once per day before going to bed. After eight weeks of this regimen, the patients were again tested for lipid profiles. The results of the tests conducted at eight weeks, showing the changes in the lipid profiles as a percentage change from the baseline, are reported in the table hereinbelow. Positive numbers reflect percentage increases and negative numbers reflect percentage decreases in this table.
  • TABLE II
    Patient Study Lipid Profile Data
    Pt. No. Total-C LDL-C ApoB Trigs HDL-C HDL2-C Lp(a)
    GROUP A
    1 −8.2 −12.0 NA −17.3 22.0 NA NA
    2 −5.9 −27.0 NA −28.7 65.0 NA NA
    3 −15.1 −13.0 NA −22.0 −9.1 NA NA
    4 −3.3 −10.0 NA 61.6 3.8 NA NA
    5 −16.5 −17.7 NA −28.8 11.1 NA NA
    6 −12.4 −25.9 NA −42.0 51.6 NA NA
    7 −24.2 −31.4 NA −39.4 12.5 NA NA
    8 −6.7 −7.4 NA −42.4 18.8 NA NA
    9 4.5 1.1 NA 7.2 9.2 NA NA
    10  2.8 −0.2 NA −2.7 22.9 NA NA
    11  −13.0 −9.4 NA −54.0 44.3 NA NA
    Mean −8.9 −13.9 NA −18.9 23.0 NA NA
    p-Value 0.0004 0.0001 0.0371 0.0068
    GROUP B
    1 −19.2 −27.1 −24.4 −33.4 20.0 22.3 −81.9
    2 −32.2 −35.7 −28.0 −60.4 4.3 3.2 −25.3
    3 −21.4 −33.6 −35.6 −33.4 30.4 38.6 −17.4
     4- −19.9 −24.6 −15.1 −20.8 9.6 16.1 −27.0
    5 −3.3 −2.1 −29.4 −41.1 5.8 2.4 −22.4
    6 PATIENT WITHDREW FROM STUDY
    7 23.1 −32.6 −42.6 −58.6 49.2 68.9 −14.3
    8 24.8 34.0 −28.4 5.5 6.5 −6.8 NA
    9 10.1 12.0 −16.8 −11.6 20.7 −12.3 40.6
    10  −2.9 −7.7 −28.0 −59.0 53.1 70.5 −41.2
    11  −10.5 −18.8 −25.3 −53.4 31.8 39.7 NA
    12  −20.0 −30.8 −30.4 11.7 21.1 25.0 −28.4
    13  17.4 16.8 −17.5 −17.5 51.3 51.9 38.5
    14  −9.4 −16.6 −32.0 −46.9 52.3 67.6 17.6
    Mean −8.7 −12.8 −32.2 −27.2 25.3 30.1 −17.9
    p-Value 0.0002 <0.0001 0.0001 <0.001 <0.0001 0.0002 <0.0188
    Combined −8.7 −13.3 Gp B −26.1 25.3 Gp B Gp B
    p-Value 0.0002 <0.0001 only <.0001 <0.0001 only only
  • The data reported in TABLE II shows that the LDL levels in the Group A patients had a mean decrease of −13.9% and triglyceride decrease of −18.9% HDL2 cholesterol levels, the beneficial cholesterol, were raised by 23.0% in this Group. Similar results were obtained with the Group B patients. These studies demonstrate that dosing the sustained release formulation during the evening hours or at night provides reductions in LDL cholesterol levels equal to immediate release niacin on a milligram per milligram basis, but superior reductions in triglyceride reductions when compared to sustained release formulations dosed during daytime hours on a milligram per milligram basis. Additionally, the increases in HDL cholesterol obtained from dosing the sustained release formulation during the evening or at night were +23.0% for one group and +25.3% for the other group. Dosing during the evening therefore provides reduction in LDL cholesterol plus significant decreases in triglycerides and increases in HDL cholesterol with once-a-day dosing.
  • Groups A and B were also tested for liver enzymes (AST, ALT and Alkaline Phosphatase), uric acid and fasting glucose levels at the start of the study described hereinabove (to form a baseline) and at two, four and eight week intervals. The results of these tests are listed in TABLES III-VII hereinbelow.
  • TABLE III
    THE EFFECT OF NIASPAN ® THERAPY ON AST (SGOT)
    LEVELS (U/L)
    (1500 mgs dosed once-a-day at night)
    (n = 28)
    Weeks of Therapy with NIASPAN ®
    Reference
    Pt# Baseline 2 Wks. 4 Wks. 8 Wks.  Range
    GROUP A
    1 28 29 25 24 0-50
    2 24 25 24 26 0-50
    3 17 18 22 21 0-50
    4 14 16 15 17 0-50
    5 22 NA 32 52 0-50
    6 21 17 17 14 0-50
    7 17 17 14 18 0-50
    8 20 21 22 22 0-50
    9 16 16 17 20 0-50
    10  18 21 21 25 0-50
    11  21 21 22 21 0-50
    GROUP B
    1 23 25 38 33 0-50
    2 20 20 21 21 0-50
    3 15 20 18 19 0-50
    4 25 22 25 26 0-50
    5 23 21 17 18 0-50
    6 PATIENT WITHDREW DUE TO FLUSHING
    7 21 18 18 19 0-50
    8 18 19 18 19 0-50
    9 15 16 18 15 0-50
    10  16 15 19 28 0-50
    11  20 22 24 28 0-50
    12  23 25 28 22 0-50
    13  20 15 20 19 0-50
    14  18 25 20 18 0-50
    Combined Mean 19.8 20.4 20.8 21.1
    Change From +3.0% +5.1% +6.6%
    Baseline
    Level of Significance: p = 0.4141
  • TABLE IV
    THE EFFECT OF NIASPAN ® THERAPY ON ALT (SGPT)
    LEVELS (U/L)
    (1500 mgs dosed once-a-day at night)
    (n = 28)
    Weeks Of Therapy With NIASPAN ®
    Reference
    Pt# Baseline 2 Wks. 4 Wks. 8 Wks. Range
    GROUP A
    1 32 28 39 30 0-55
    2 24 25 23 26 0-55
    3 18 23 30 30 0-55
    4 7 13 14 14 0-55
    5 14 NA 43 46 0-55
    6 22 11 14 10 0-55
    7 9 7 11 7 0-55
    8 16 18 23 21 0-55
    9 14 17 20 14 0-55
    10  14 15 17 19 0-55
    11  18 18 20 16 0-55
    GROUP B
    1 16 17 27 29 0-55
    2 16 14 15 22 0-55
    3 13 21 13 16 0-55
    4 23 20 26 17 0-55
    5 21 23 17 15 0-55
    6 PATIENT WITHDREW DUE TO FLUSHING
    7 21 16 18 21 0-55
    8 18 20 17 18 0-55
    9 11 5 11 8 0-55
    10  8 10 14 17 0-55
    11  17 12 18 16 0-55
    12  14 18 20 16 0-55
    13  14 NA 11 10 0-55
    14  23 23 19 19 0-55
    Combined Mean 17.7 17.5 19.3 18.2
    Change From −1.1% 9.0% +2.8%
    Baseline
    Level of Significance: p = 0.3424
  • TABLE V
    THE EFFECT OF NIASPAN ® THERAPY ON ALKALINE
    PHOSPHATASE LEVELS (U/L)
    (1500 mgs dosed once-a-day at night)
    (n = 28)
    Weeks Of Therapy With NIASPAN ®
    Pt# Baseline 2 Wks. 4 Wks. 8 Wks. Reference Range
    GROUP A
    1 52 56 57 55 20-140
    2 103 100 89 102 20-140
    3 54 45 53 51 20-140
    4 70 68 71 91 20-140
    5 77 NA 74 81 20-140
    6 55 48 49 51 20-140
    7 72 71 79 75 20-140
    8 55 49 47 50 20-140
    9 53 55 56 45 20-140
    10  74 73 75 75 20-140
    11  18 18 20 16 20-140
    GROUP B
    1 73 67 89 95 20-140
    2 82 64 72 71 20-140
    3 73 69 72 82 20-140
    4 37 36 37 38 20-140
    5 65 53 54 61 20-140
    6 PATIENT WITHDREW DUE TO FLUSHING
    7 64 58 58 58 20-140
    8 79 78 65 73 20-140
    9 94 92 103 93 20-140
    10  69 67 70 65 20-140
    11  59 67 63 72 20-140
    12  65 59 59 63 20-140
    13  64 68 66 64 20-140
    14  72 61 59 64 20-140
    Combined 66.5 61.5 63.3 65.8
    Mean
    Change −6.1% −3.4% +0.005%
    From
    Baseline
    Level of Significance: p == 0.0236
  • TABLE VI
    THE EFFECT OF NIASPAN ® THERAPY ON URIC ACID
    LEVELS (mg/dL)
    (1500 mgs dosed once-a-day at night)
    (n = 28)
    Weeks Of Therapy With NIASPAN ®
    Pt# Baseline 2 Wks. 4 Wks. 8 Wks. Reference Range
    GROUP A
    1 5.2 5.0 4.8 4.3 4.0-8.5
    2 4.0 4.6 4.5 6.2 2.5-7.5
    3 6.3 7.0 6.5 6.2 4.0-8.5
    4 3.1 4.6 4.2 3.8 2.5-7.5
    5 3.4 NA 3.3 4.2 2.5-7.5
    6 6.6 5.5 5.6 4.7 4.0-8.5
    7 3.8 4.5 4.3 4.9 2.5-7.5
    8 4.4 3.8 5.1 4.5 2.5-7.5
    9 3.9 4.5 4.6 3.5 2.5-7.5
    10  2.6 2.9 2.8 2.7 2.5-7.5
    11  4.7 5.5 5.2 5.3 2.5-7.5
    GROUP B
    1 3.7 4.2 4.7 3.5 2.5-7.5
    2 2.8 3.5 3.6 2.3 4.0-8.5
    3 4.2 5.3 5.5 5.3 2.5-7.5
    4 4.7 3.9 5.1 3.6 4.0-8.5
    5 3.7 4.1 4.1 3.8 2.5-7.5
    6 PATIENT WITHDREW DUE TO FLUSHING
    7 5.8 6.6 6.6 6.8 2.5-7.5
    8 4.7 4.3 5.4 5.6 2.5-7.5
    9 3.7 4.6 5.1 3.8 2.5-7.5
    10  4.2 5.0 4.4 8.5 2.5-7.5
    11  1.9 3.0 2.8 5.0 2.5-7.5
    12  5.6 5.4 6.2 5.6 4.0-8.5
    13  4.2 4.6 4.6 5.3 2.5-7.5
    14  5.5 5.4 6.1 5.3 2.5-7.5
    Combined 4.54 4.82 4.92 4.86 *p = 0.3450
    Mean
    Change +6.2% +8.4% +7.0%
    From
    Baseline
    *Level of Significance: p == 0.3450
  • TABLE VII
    THE EFFECT OF NIASPAN ® THERAPY ON FASTING
    GLUCOSE LEVELS (mg/dL)
    (1500 mgs dos<<d once-a-day at night)
    (n = 28)
    Weeks Of Therapy With NIASPAN ®
    Reference
    Pt# Baseline 2 Wks. 4 Wks. 8 Wks. Range
    GROUP A
    1 114 122 123 110 70-115
    2 101 105 107 101 80-125
    3 99 98 109 103 70-115
    4 100 118 94 94 80-125
    5 89 NA 82 103 80-125
    6 97 103 94 107 70-115
    7 85 107 100 94 80-125
    8 98 107 103 101 80-125
    9 97 97 100 110 80-125
    10  94 101 111 97 70-115
    11  102 103 95 95 80-125
    GROUP B
    1 101 97 83 99 70-115
    2 90 95 96 89 80-125
    3 96 98 95 97 70-115
    4 116 139 113 125 80-125
    5 88 92 91 95 70-115
    6 PATIENT WITHDREW DUE TO FLUSHING
    7 106 114 118 117 70-115
    8 95 106 106 108 70-115
    9 81 92 84 92 70-115
    10  108 117 122 105 70-115
    11  85 106 106 108 70-115
    12  92 89 101 86 80-125
    13  99 105 94 100 70-125
    14  100 108 84 107 70-125
    Combined 98.4 105.8 101.6 102.3
    Mean
    Change From +7.5% +3.3% +4.0%
    Baseline
    Level of Significance: p = 0.0021
  • TABLE VIII
    A Comparison of Changes in Liver Function Tests
    DOSE:
    0 500 1000 1500 2000 2500 3000 TOTAL
    McKenney SRb Niacina
    AST 23.8 27.9 40.4 36.6 56.5 NA 97
    % — 117 170 154 237 NA 408
    Invention Dosagec
    AST 24.3 NA 23.7 27.5 26.6 27.6 27.8
    % — NA 98 113 109 114 114
    McKenney SR Niacin
    ALT 25.6 29.5 36.3 39.0 59.1 NA 100.0
    % — 115 142 152 231 NA 391
    Invention Dosage
    ALT 21.4 NA 18.7 22.6 21.3 22.4 21.8
    % — NA 87 106 100 105 102
    McKenney SR Niacin
    ALK 95   95 106 105 136 NA 135
    % — 100 112 111 143 NA 142
    Invention Dosage
    ALK 74.7 NA 73.9 76.1 73.4 76.7 78
    % — NA 99 102 98 103 104
    McKenney SR Niacin
    Drop — 0 2 2 7 NA 7 18
    n — — — — — — — 23
    % — 0 9 9 30 NA 30 78
    Invention Dosage
    Drop — — 0 0 0 0 0 0
    n — — 26 67 97 35 15 240
    % — — 0 0 0 0 0 0
    1 year — — 15 46 77 31 15 184
    1 year — — 58 69 79 89 100 77
    aDosed twice-per-day as described in “A Comparison of the Efficacy and Toxic Effects of Sustained-vs Immediate Release Niacin in Hypercholesterolemic Patients” by McKenney et al. Journal of the American Medial Association. Mar. 2, 1994; 271, No. 9, pages 672-677.
    bSR is “sustained release”
    cDosed once-per-day at night
  • In order to provide a comparison between the state of the art prior to the present invention, and in order to quantify the magnitude of the improvement that the invention provides over the prior art, another study was conducted. This study included 240 patients dosed according to the present invention as described hereinabove. Compared to this group was the group of patients studied by McKenney et al., as reported hereinabove. The results of this study are reported in TABLE VIII hereinbelow.
  • The results of the comparison of the studies reported in TABLE VIII show that the control group (the McKenney group) had 18 of 23, or 78 percent of the patients therein drop out of the test because of an increase in their respective liver function tests. The patients withdrew at the direction of the investigator. In comparison, a group of 240 patients treated according to the present invention had zero patients drop out, based upon the same criteria for withdrawal. The tests results reported above indicate that this sustained release dosage form caused no elevation in liver function tests (i.e., no liver damage), no elevations in uric acid and only a small, 7.5% increase in fasting glucose levels which in fact decreased during continued therapy.
  • Thus it should be evident that the compositions and method of the present invention are highly effective in controlling hyperlipidemia in hyperlipidemics, by reducing the levels of LDL cholesterol, triglyceride and Lp(a) while increasing HDL2 cholesterol levels. The present invention is also demonstrated not to cause elevations in liver function tests, uric acid or glucose levels for the hyperlipidemics.
  • Based upon the foregoing disclosure, it should now be apparent that the use of the compositions and methods described herein will carry out the objects set forth hereinabove. It is, therefore, to be understood that any variations in sustained release formulation evident fall within the scope of the claimed invention and thus, the selection of specific component elements can be determined without departing from the spirit of the invention herein disclosed and described. In particular, sustained release excipients, binders and processing aids according to the present invention are not necessarily limited to those exemplified hereinabove. Thus, the scope of the invention shall include all modifications and variations that my fall within the scope of the attached claims.

Claims (12)

1. A method of treating hyperlipidemia in a hyperlipidemic comprising dosing the hyperlipidemic with an effective antihyperlipidemic amount of nicotinic acid or a compound metabolized to nicotinic acid by the body, once per day in the evening or at night combined with a pharmaceutically acceptable carrier, to produce a reduction in total and LDL cholesterol, triglycerides and Lp(a), with a significant increase in HDL cholesterol.
2. The method according to claim 1, wherein the hyperlipidemic is dosed with from about 250 milligrams to about 3000 milligrams by weight of nicotinic acid.
3. The method according to claim 1, wherein said method causes little or no serious liver damage, uric acid increases or elevations in fasting glucose levels.
4. The method according to claim 1, wherein the release rate of said nicotinic acid or compound metabolized by the body to nicotinic acid is from about 2.0% per hour to about 25% per hour.
5. The method according to claim 1, wherein said nicotinic acid or compound metabolized to nicotinic acid by the body is prepared by formulating said nicotinic acid or compound metabolized to nicotinic acid into a sustained release formulation or tablet with from about 5% to about 50% parts by weight of hydroxypropyl methylcellulose per 400 parts by weight of said formulation or tablet.
6. The method according to claim 1, wherein said nicotinic acid or compound metabolized to nicotinic acid by the body is dosed in the form of a sustained release formulation or tablet containing from about 1 to about 4 parts by weight of binder per 400 parts by weight of said formulation or tablet.
7. The method according to claim 6, wherein said binder is a polymer having the repeating polymerization unit 1-ethenyl-2-pyrrolidone.
8. The method according to claim 1, wherein said nicotinic acid or compound metabolized to nicotinic acid by the body is dosed in the form of a sustained release formulation or tablet comprising from about 0.5 to about 2.5 parts by weight of a lubricating agent per 400 parts by weight of said formulation or tablet.
9. The method according to claim 8, wherein said lubricating agent is selected from the group consisting of: stearic acid and magnesium stearate.
10. The method according to claim 1, wherein the compound metabolized to nicotinic acid by the body is nicotinyl alcohol tartrate.
11. The method according to claim 10, wherein the amount of nicotinyl alcohol tartrate is from about 100 milligrams to about 500 milligrams per dosage unit.
12. The method according to claim 1, wherein the compound metabolized to nicotinic acid by the body is selected from the group consisting of: d-glucitol hexanicotinate, aluminum nicotinate and 1-alpha-tocopheryl nicotinate.
US12/350,654 1993-09-20 2009-01-08 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor Abandoned US20090186925A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/350,654 US20090186925A1 (en) 1993-09-20 2009-01-08 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US12/756,288 US20110003783A1 (en) 1993-09-20 2010-04-08 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US13/406,038 US20120157503A1 (en) 1993-09-20 2012-02-27 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US12439293A 1993-09-20 1993-09-20
US08/368,378 US6080428A (en) 1993-09-20 1995-01-14 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US08/814,974 US6129930A (en) 1993-09-20 1997-03-06 Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US47832500A 2000-01-06 2000-01-06
US10/444,145 US7998506B2 (en) 1993-09-20 2003-05-23 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US11/757,967 US20070224270A1 (en) 1993-09-20 2007-06-04 Nicotinic Acid Compositions For Treating Hyperlipidemia and Related Methods Therefor
US12/350,654 US20090186925A1 (en) 1993-09-20 2009-01-08 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/757,967 Continuation US20070224270A1 (en) 1993-09-20 2007-06-04 Nicotinic Acid Compositions For Treating Hyperlipidemia and Related Methods Therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/756,288 Continuation US20110003783A1 (en) 1993-09-20 2010-04-08 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor

Publications (1)

Publication Number Publication Date
US20090186925A1 true US20090186925A1 (en) 2009-07-23

Family

ID=29783152

Family Applications (13)

Application Number Title Priority Date Filing Date
US08/962,422 Expired - Lifetime US6676967B1 (en) 1993-09-20 1997-10-31 Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US10/444,145 Expired - Fee Related US7998506B2 (en) 1993-09-20 2003-05-23 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US11/757,959 Abandoned US20070237819A1 (en) 1993-09-20 2007-06-04 Nicotinic Acid Compositions For Treating Hyperlipidemia and Related Methods Therefor
US11/757,967 Abandoned US20070224270A1 (en) 1993-09-20 2007-06-04 Nicotinic Acid Compositions For Treating Hyperlipidemia and Related Methods Therefor
US11/757,963 Abandoned US20070225341A1 (en) 1993-09-20 2007-06-04 Nicotinic Acid Compositions For Treating Hyperlipidemia and Related Methods Therefor
US11/757,965 Abandoned US20070225342A1 (en) 1993-09-20 2007-06-04 Nicotinic Acid Compositions For Treating Hyperlipidemia and Related Methods Therefor
US12/187,960 Abandoned US20090036500A1 (en) 1993-09-20 2008-08-07 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US12/350,654 Abandoned US20090186925A1 (en) 1993-09-20 2009-01-08 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US12/423,027 Abandoned US20090203748A1 (en) 1993-09-20 2009-04-14 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US12/756,288 Abandoned US20110003783A1 (en) 1993-09-20 2010-04-08 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US13/105,115 Abandoned US20110245300A1 (en) 1993-09-20 2011-05-11 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US13/105,057 Abandoned US20110245298A1 (en) 1993-09-20 2011-05-11 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US13/406,038 Abandoned US20120157503A1 (en) 1993-09-20 2012-02-27 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor

Family Applications Before (7)

Application Number Title Priority Date Filing Date
US08/962,422 Expired - Lifetime US6676967B1 (en) 1993-09-20 1997-10-31 Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US10/444,145 Expired - Fee Related US7998506B2 (en) 1993-09-20 2003-05-23 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US11/757,959 Abandoned US20070237819A1 (en) 1993-09-20 2007-06-04 Nicotinic Acid Compositions For Treating Hyperlipidemia and Related Methods Therefor
US11/757,967 Abandoned US20070224270A1 (en) 1993-09-20 2007-06-04 Nicotinic Acid Compositions For Treating Hyperlipidemia and Related Methods Therefor
US11/757,963 Abandoned US20070225341A1 (en) 1993-09-20 2007-06-04 Nicotinic Acid Compositions For Treating Hyperlipidemia and Related Methods Therefor
US11/757,965 Abandoned US20070225342A1 (en) 1993-09-20 2007-06-04 Nicotinic Acid Compositions For Treating Hyperlipidemia and Related Methods Therefor
US12/187,960 Abandoned US20090036500A1 (en) 1993-09-20 2008-08-07 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor

Family Applications After (5)

Application Number Title Priority Date Filing Date
US12/423,027 Abandoned US20090203748A1 (en) 1993-09-20 2009-04-14 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US12/756,288 Abandoned US20110003783A1 (en) 1993-09-20 2010-04-08 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US13/105,115 Abandoned US20110245300A1 (en) 1993-09-20 2011-05-11 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US13/105,057 Abandoned US20110245298A1 (en) 1993-09-20 2011-05-11 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US13/406,038 Abandoned US20120157503A1 (en) 1993-09-20 2012-02-27 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor

Country Status (1)

Country Link
US (13) US6676967B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100076033A1 (en) * 1993-09-20 2010-03-25 Eugenio Cefali Methods For Treating Hyperlipidemia with Intermediate Release Nicotinic Acid Compositions Having Unique Biopharmaceutical Characteristics

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0643965B1 (en) * 1993-09-20 2013-05-08 Abbott Laboratories Nicotinic acid compositions for treating hyperlipidemia
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US20080045573A1 (en) * 1993-09-20 2008-02-21 Bova David J Methods and Sustained Release Nicotinic Acid Compositions for Treating Hyperlipidemia
AU2003267245C1 (en) 2002-09-20 2008-05-29 Promega Corporation Luminescence-based methods and probes for measuring cytochrome P450 activity
PL364348A1 (en) 2004-01-12 2005-07-25 PHARMENA Sp.z o.o. Application of quaternary pyridine salts as vessel protection agent
WO2006130551A2 (en) * 2005-05-31 2006-12-07 Promega Corporation Luminogenic and fluorogenic compounds and methods to detect molecules or conditions
ATE548035T1 (en) * 2005-07-11 2012-03-15 Cortria Corp FORMULATIONS FOR TREATING LIPOPROTEIN ABNORMALITIES WITH A STATIN AND A METHYLNICOTINAMIDE DERIVATIVE
US20070072910A1 (en) * 2005-09-29 2007-03-29 Smith Michael L Compositions and methods for lowering plasma concentrations of low density lipoproteins in humans
US20090069275A1 (en) * 2006-02-17 2009-03-12 Rocca Jose G Low flush niacin formulation
WO2007103540A2 (en) * 2006-03-08 2007-09-13 Pharmena North America Inc. Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries
US8658160B1 (en) 2006-10-17 2014-02-25 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Composition and method for cancer chemoprevention
WO2008100249A1 (en) * 2007-02-13 2008-08-21 Kos Life Sciences, Inc. Low flush niacin formulation
WO2009067684A1 (en) * 2007-11-21 2009-05-28 Capricorn Pharma Inc. Modified release niacin formulations
RU2010153904A (en) * 2008-06-02 2012-07-20 Др. Редди'С Лабораторис Лтд. (In) Niacin-containing Compositions with Modified Release
BRPI0913425A2 (en) * 2008-06-02 2015-11-24 Reddys Lab Ltd Dr modified release niacin formulations
US20110123609A1 (en) * 2008-07-19 2011-05-26 Sunil Shantwan Borude Multiple unit dosage form of niacin
US8288559B2 (en) * 2008-08-18 2012-10-16 Promega Corporation Luminogenic compounds and methods to detect cytochrome P450 3A enzymes
CA2841748C (en) 2011-07-15 2021-06-15 Nusirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
JP6469015B2 (en) 2012-11-13 2019-02-13 ニューサート サイエンシーズ， インコーポレイテッド Compositions and methods for increasing energy metabolism
CN105228627B (en) 2013-03-15 2018-07-13 纽斯尔特科学公司 Leucine and niacin reduce lipid level
WO2015116867A1 (en) 2014-01-29 2015-08-06 Promega Corporation Quinone-masked probes as labeling reagents for cell uptake measurements
EP3110507B1 (en) 2014-02-27 2020-11-18 NuSirt Sciences, Inc. Compositions and methods for the reduction or prevention of hepatic steatosis
US10366642B2 (en) * 2016-12-01 2019-07-30 Disney Enterprises, Inc. Interactive multiplane display system with transparent transmissive layers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268181A (en) * 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis

Family Cites Families (296)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA603690A (en) 1960-08-16 Wynn Pharmacal Corporation Quinidine gluconate sustained medication tablet
US2510164A (en) 1945-04-24 1950-06-06 Us Agriculture Water-insoluble derivatives of nicotinic acid and process for preparing them
US2540979A (en) 1948-04-24 1951-02-06 Smith Kline French Lab Enteric coating
US2749274A (en) 1952-05-06 1956-06-05 Bristol Lab Inc Stable aqueous procaine penicillin suspension
US2798837A (en) 1952-11-20 1957-07-09 Sahyun Melville Achlorhydria composition
US2851453A (en) 1954-08-09 1958-09-09 Smith Kline French Lab Cellulose derivative product, compositions comprising the same and their preparation
US2798838A (en) 1954-11-10 1957-07-09 Smith Kline French Lab Method of preparing acetophenetidin tablets
US2805977A (en) 1955-01-04 1957-09-10 Smith Kline French Lab Sustained release pharmaceutical preparation
US2857313A (en) 1956-03-27 1958-10-21 Ciba Pharm Prod Inc Self-lubricating granulation
US2887436A (en) 1956-05-28 1959-05-19 Pfizer & Co C Pharmaceutical compositions
US3193461A (en) 1957-06-14 1965-07-06 Sophie R Gordon Correcting blood changes with niacin, vitamin a, and riboflavin
US2957804A (en) 1958-06-06 1960-10-25 Harlan R Shuyler Pesticide
US3062720A (en) 1959-05-20 1962-11-06 Philips Roxane Sustained release pharmaceutical tablet
FR1302362A (en) 1959-10-23 1962-08-31 Olin Mathieson Process for the preparation of time-release pills
US3065143A (en) 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US3108046A (en) 1960-11-25 1963-10-22 Smith Kline French Lab Method of preparing high dosage sustained release tablet and product of this method
US3143465A (en) 1961-06-19 1964-08-04 Wallace & Tiernan Inc Pharmaceutical preparations comprising phosphorus containing cation exchange resins having a basic drug adsorbed thereon; and treatment therewith
US3143469A (en) 1961-06-26 1964-08-04 Debay Andre George Anti-cholesterol nicotinic acid nu-oxide
US3116204A (en) 1961-11-09 1963-12-31 Merck & Co Inc Pharmaceutical compositions and method of preparing the same
US3134719A (en) 1962-04-05 1964-05-26 American Cyanamid Co Calcium phosphates in tablet compressing
US3210413A (en) 1962-05-17 1965-10-05 Smith Kline French Lab Antihypercholesterolemic agents
US3147187A (en) 1962-09-10 1964-09-01 Don Hall Lab Sustained release pharmaceutical
US3336200A (en) 1963-05-28 1967-08-15 Warner Lambert Pharmaceutical Tablet structure
US3272832A (en) 1963-07-03 1966-09-13 Fujisawa Pharmaceutical Co Nicotinic acid derivatives and process for the preparation thereof
GB1064252A (en) 1963-09-19 1967-04-05 Ici Ltd Amides and pharmaceutical compositions containing them
DE1228029C2 (en) 1964-05-09 1973-05-17 Merck Ag E Process for the production of tablets by pressing powder mixtures without prior granulation
US3930017A (en) 1965-10-07 1975-12-30 Horst Kummer Lowering blood cholesterol and lipid levels
US3849554A (en) 1965-12-01 1974-11-19 Nasa Reduction of blood serum cholesterol
US3862332A (en) 1967-05-11 1975-01-21 Dow Chemical Co Method of lowering serum cholesterol
US3639636A (en) 1967-06-01 1972-02-01 Dow Chemical Co Method of lowering serum cholesterol
US3626071A (en) 1968-03-08 1971-12-07 Richardson Merrell Inc Compositions and methods for reducing cholesterol in the blood
US3495011A (en) 1968-10-28 1970-02-10 Unimed Inc Reduction of blood level cholesterol
US3634584A (en) 1969-02-13 1972-01-11 American Home Prod Sustained action dosage form
US3590117A (en) 1969-03-24 1971-06-29 Richardson Merrell Inc Long-lasting troche containing guar gum
US3629393A (en) 1969-09-11 1971-12-21 Nikken Chemicals Co Ltd Release-sustaining-tablet
US3870790A (en) 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US3721735A (en) 1970-07-15 1973-03-20 C Thiffault Compositions for and method of lowering cholesterol levels
IL38154A (en) 1970-11-18 1974-05-16 Egyt Gyogyszervegyeszeti Gyar The preparation of bis-(p-chlorophenoxy)-acetyl-urea and pharmaceutical composition containing it
US3709991A (en) 1970-11-23 1973-01-09 Hoffmann La Roche Hypolipidemic method
GB1338235A (en) 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
US3859437A (en) 1972-06-02 1975-01-07 Intellectual Property Dev Corp Reducing cholesterol levels
US3795691A (en) 1971-06-23 1974-03-05 American Home Prod Cholesterol-lowering agents
US3773920A (en) 1971-07-14 1973-11-20 Nikken Chemicals Co Ltd Sustained release medicinal composition
US3923972A (en) 1971-10-12 1975-12-02 Monsanto Co Method of lowering blood cholesterol level
US4237118A (en) 1972-03-06 1980-12-02 Howard Alan N Dietary supplement and dietary methods employing said supplement for the treatment of obesity
US3951821A (en) 1972-07-14 1976-04-20 The Dow Chemical Company Disintegrating agent for tablets
JPS4954572A (en) 1972-09-29 1974-05-27
US3992536A (en) 1972-11-11 1976-11-16 Boehringer Ingelheim Gmbh Pharmaceutical compositions containing a 1-phenyl-2,2,4,4-C1 -C2 alkyl-3-[4-phenyl of pyridyl)-piperazino]-cyclobutanol-(1) and method of use
US3959492A (en) 1972-12-08 1976-05-25 Istituto Chemioterapico Italiano Method for reducing serum blood cholesterol
US4180064A (en) 1972-12-27 1979-12-25 Alza Corporation System for delivering agent to environment of use over prolonged time
US4034087A (en) 1973-12-17 1977-07-05 The Regents Of The University Of Michigan Pharmaceutical composition and process of treatment
US4117111A (en) 1973-04-23 1978-09-26 Monsanto Company Method for lowering blood cholesterol level
US3868416A (en) 1973-10-01 1975-02-25 American Cyanamid Co Hypolipidemic 4-(monoalkylamino)benzoic acid derivatives
DE2363511A1 (en) 1973-12-20 1975-07-10 Bayer Ag PYRAZOLE DERIVATIVES, THE PROCESS FOR THEIR MANUFACTURING AND THEIR USE AS A MEDICINAL PRODUCT
US4182902A (en) 1973-12-27 1980-01-08 Siegfried Aktiengesellschaft Novel cholesterol-lowering compounds
US3864416A (en) 1974-03-18 1975-02-04 Universal Oil Prod Co Separation of tetra-alkyl substituted aromatic hydrocarbon isomers
US3965255A (en) 1974-05-01 1976-06-22 E. E. Eljim Ecology Ltd. Controlled drug releasing preparations
US4014987A (en) 1974-06-04 1977-03-29 Alza Corporation Device for delivery of useful agent
US4166902A (en) 1974-10-14 1979-09-04 Paolo Ferruti High polymers containing nicotinic acid, process for their preparation and their use
IT1044798B (en) 1974-10-15 1980-04-21 Ferruti Paolo HIGH POLYMERS CONTAINING NICOTINIC ACID PROCESS FOR THEIR PREPARATION AND USE
JPS51125755A (en) * 1975-04-02 1976-11-02 Eisai Co Ltd A method for treating hyperpiesia
US4011339A (en) 1975-08-15 1977-03-08 Sandoz, Inc. Hypolipidemic allene carboxylic acids
JPS5231981A (en) 1975-08-18 1977-03-10 Takeda Chem Ind Ltd Microcapsule preparation method
US4034758A (en) 1975-09-08 1977-07-12 Alza Corporation Osmotic therapeutic system for administering medicament
US3977404A (en) 1975-09-08 1976-08-31 Alza Corporation Osmotic device having microporous reservoir
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4014334A (en) 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4058122A (en) 1976-02-02 1977-11-15 Alza Corporation Osmotic system with laminated wall formed of different materials
US4126672A (en) 1976-02-04 1978-11-21 Hoffmann-La Roche Inc. Sustained release pharmaceutical capsules
US4167558A (en) 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4140755A (en) 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4178387A (en) 1976-03-30 1979-12-11 William H. Rorer, Inc. Method for the treatment of arrhythmia
US4203439A (en) 1976-11-22 1980-05-20 Alza Corporation Osmotic system with volume amplifier for increasing amount of agent delivered therefrom
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4169944A (en) 1977-09-19 1979-10-02 University Patents, Inc. Cholesterol biosynthesis inhibitors
US4348399A (en) 1978-02-02 1982-09-07 American Cyanamid Company Antiatherosclerotic and hypolipidemic 4-(monoalkylamino)phenyl alkane, alkene and alkyne carbinols, aldehydes, carboxylic acids and derivatives
US4283382A (en) 1977-12-28 1981-08-11 Eastman Kodak Company Fluorescent labels comprising rare earth chelates
US4211783A (en) 1978-03-20 1980-07-08 American Cyanamid Company Hypolipidemic and antiatherosclerotic novel 4-(aralkyl- and heteroarylalkylamino)phenyl compounds
US4205085A (en) 1978-03-09 1980-05-27 American Cyanamid Company Hypolipidemic and antiatherosclerotic 4-(polyfluoroalkylamino)phenyl compounds
US4230878A (en) 1978-03-08 1980-10-28 American Cyanamid Company Hypolipidemic and antiatherosclerotic 4-[(cyclopropyl alkyl)amino]benzoic acids and derivatives
DE2903579A1 (en) 1978-02-03 1979-08-09 Sigma Tau Ind Farmaceuti USE OF ACETYL CARNITINE AND OTHER ACYLDER DERIVATIVES OF CARNITINE FOR THE TREATMENT OF HYPERLIPOPROTEINEMIC AND HYPERLIMPIDAEMIA AND MEDICINAL PRODUCTS
DE2903558C2 (en) 1978-02-03 1994-09-01 Sigma Tau Ind Farmaceuti Use of L-carnitine
US4310545A (en) 1978-03-09 1982-01-12 American Cyanamid Company Hypolipidemic and antiatherosclerotic 4-(polyfluoroalkylamino) phenyl compounds
US4305959A (en) 1978-03-09 1981-12-15 American Cyanamid Company Hypolipidemic and antiatherosclerotic 4-(polyfluoro-alkylamino)phenyl compounds
US4318914A (en) 1978-03-09 1982-03-09 American Cyanamid Company Hypolipidemic and antiatherosclerotic 4-(polyfluoro-alkylamino)phenyl compounds
DD146547A5 (en) 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim MEDICINAL RETARDANT SHAPE WITH UNFORGETTABLE POROESEN DIFFUSION SHELLS
EP0010061B1 (en) 1978-09-25 1983-07-13 Stuart John Mc Farlane Pharmaceutical preparations containing a mollusc extract
US4485105A (en) 1978-10-12 1984-11-27 American Cyanamid Company Method of treating hyperlipidemia with 4-(monoalkylamino)benzoic acid amides
US4321268A (en) 1979-02-08 1982-03-23 Merz & Co. Certain substituted phenyl esters of nicotinic acid, compositions and methods of using same
DE2905979C2 (en) 1979-02-16 1981-01-22 Carl-Jacob Gatzen Use of acetylated, distilled monoglycerides for the treatment of lipid metabolic disorders in humans
JPS55153715A (en) 1979-05-18 1980-11-29 Nikken Kagaku Kk Prolonged granule of theophylline
US4357469A (en) 1979-06-14 1982-11-02 Forest Laboratories, Inc. Carrier base material for prolonged release therapeutic compositions
US4226849A (en) 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4382143A (en) 1979-07-23 1983-05-03 American Cyanamid Company Hypolipidemic and antiatherosclerotic novel (monosubstituted-amino)heteroaryl carboxylic acids and analogs
US4251519A (en) 1979-07-30 1981-02-17 Anheuser-Busch, Incorporated Process for the prevention and reduction of elevated blood cholesterol and triglycerides levels
US4309404A (en) 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4248857A (en) 1979-08-09 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4353887A (en) 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
US4568547A (en) 1979-08-30 1986-02-04 Herschler R J Solid pharmaceutical compositions comprising MSM and their production
US4285951A (en) 1979-09-07 1981-08-25 Warner-Lambert Company 2,2-Dimethyl-5-(2,5-dimethylphenoxy)pentyl ester of 3-pyridine carboxylic acid and use as an anti-atherosclerotic agent
US4440940A (en) 1979-10-17 1984-04-03 American Cyanamid Company Anti-atherosclerotic agents
IT1126575B (en) * 1979-12-07 1986-05-21 Causyth Chim Farm COMPOUND WITH ANTI-INFLAMMATORY, ANALGESIC AND ANTI-PIRETIC ACTIVITY, PROCESS FOR ITS PREPARATION, AND RELATED PHARMACEUTICAL COMPOSITIONS
FR2471186A1 (en) 1979-12-10 1981-06-19 Roussel Uclaf NEW COLIC DELITESCENCE TABLETS AND THEIR PREPARATION PROCESS
US4259314A (en) 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4308251A (en) 1980-01-11 1981-12-29 Boots Pharmaceuticals, Inc. Controlled release formulations of orally-active medicaments
DE3000979A1 (en) 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach NEW DIPYRIDAMOL RETARD FORMS AND METHOD FOR THEIR PRODUCTION
US4279898A (en) 1980-04-22 1981-07-21 Research Foundation Of The City University Of New York In vivo inhibitors of cholesterol biosynthesis
US4282233B1 (en) 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
US4362711A (en) 1980-07-11 1982-12-07 Evreka Inc. Blood cholesterol level reducing agent and method
US4291030A (en) 1980-07-25 1981-09-22 Unimed, Inc. Method of lowering blood cholesterol
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4465660A (en) 1981-04-01 1984-08-14 Mead Johnson & Company Sustained release tablet containing at least 95 percent theophylline
US4375468A (en) 1981-07-13 1983-03-01 Verex Laboratories, Inc. Constant order release aspirin composition and method of treating arthritis
JPS5839618A (en) 1981-09-04 1983-03-08 Chugai Pharmaceut Co Ltd Long-acting laminated tablet
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4525345A (en) 1981-12-24 1985-06-25 Verex Laboratories, Inc. Constant order release, solid dosage indomethacin formulation and method of treating arthritis and other inflammatory conditions
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4428951A (en) 1982-04-22 1984-01-31 Fujisawa Pharmaceutical Co., Ltd. Long acting pharmaceutical composition
FR2525474A1 (en) 1982-04-26 1983-10-28 Roussel Uclaf NEW ORAL PHARMACEUTICAL FORM OF CLOMETACIN
US4556678A (en) 1982-06-24 1985-12-03 Key Pharmaceuticals, Inc. Sustained release propranolol tablet
US4457907A (en) 1982-08-05 1984-07-03 Clear Lake Development Group Composition and method for protecting a therapeutic drug
FR2535202B1 (en) 1982-11-03 1985-08-09 Fabre Sa Pierre CONTROLLED RELEASE THEOPHYLLIN TABLETS AND PROCESS FOR THEIR MANUFACTURE
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4472436A (en) 1982-12-06 1984-09-18 Neo-Bionics, Inc. Increasing HDL-cholesterol levels with phenylethylamine derivatives
US4522804A (en) 1983-01-03 1985-06-11 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of propranolol
US4461759A (en) 1983-01-03 1984-07-24 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of veropamil
JPS59155309A (en) 1983-02-22 1984-09-04 Teijin Ltd Active type vitamin d3 composition and its preparation
US4576604A (en) 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
US4673405A (en) 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
DE3435325A1 (en) 1983-04-09 1986-04-17 Nikken Chemicals Co., Ltd., Tokio/Tokyo LONG-TERM THEOPHYLLIN TABLET AND METHOD FOR THE PRODUCTION THEREOF
DE3314003A1 (en) 1983-04-18 1984-10-18 Boehringer Ingelheim KG, 6507 Ingelheim DIVISIBLE TABLET WITH DELAYED ACTIVE SUBSTANCE RELEASE AND METHOD FOR THE PRODUCTION THEREOF
DE3315877A1 (en) 1983-05-02 1984-11-08 Merz + Co GmbH & Co, 6000 Frankfurt N-OXIDES OF PYRIDYL CARBONIC ACID ESTERS, A METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS
NZ208143A (en) 1983-05-19 1986-12-05 Merrell Dow Pharma Controlled release pharmaceutical tablet;one of compressed faces sloped
US4882167A (en) 1983-05-31 1989-11-21 Jang Choong Gook Dry direct compression compositions for controlled release dosage forms
US4571333A (en) 1983-06-14 1986-02-18 Syntex (U.S.A.) Inc. Controlled release naproxen and naproxen sodium tablets
JPS60874A (en) 1983-06-17 1985-01-05 Hiroki Jiyufuku Compressing apparatus for refuse
US4505890A (en) 1983-06-30 1985-03-19 E. R. Squibb & Sons, Inc. Controlled release formulation and method
US4539198A (en) 1983-07-07 1985-09-03 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
US4690824A (en) 1983-07-07 1987-09-01 Redi-Rowell, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
US4684516A (en) 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
JPS6035385A (en) 1983-08-03 1985-02-23 Hitachi Maxell Ltd Disk cartridge
EP0135109B1 (en) 1983-08-19 1988-02-17 Nissan Chemical Industries Ltd. Antiatherosclerotic agent
US4749575A (en) 1983-10-03 1988-06-07 Bio-Dar Ltd. Microencapsulated medicament in sweet matrix
US4605666A (en) 1983-10-24 1986-08-12 Basf Corporation Process for preparing spray-dried powders containing a water-soluble vitamin and powders prepared thereby
US4680323A (en) 1983-12-01 1987-07-14 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
GB2154874B (en) 1984-02-29 1987-11-04 Sandoz Ltd Bromoscriptine compositions
US4795327A (en) 1984-03-26 1989-01-03 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
US4849229A (en) 1984-03-26 1989-07-18 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
US4540566A (en) 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
JPS60209523A (en) 1984-04-03 1985-10-22 Mitsubishi Petrochem Co Ltd Antilipemic agent
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4603142A (en) 1984-06-01 1986-07-29 Wisconsin Alumni Research Foundation Cholesterol lowering method of use
US4713245A (en) 1984-06-04 1987-12-15 Mitsui Toatsu Chemicals, Incorporated Granule containing physiologically-active substance, method for preparing same and use thereof
JPS6124516A (en) 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd Long active tablet
US4610870A (en) 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
US4678516A (en) 1984-10-09 1987-07-07 The Dow Chemical Company Sustained release dosage form based on highly plasticized cellulose ether gels
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4747881A (en) 1985-02-05 1988-05-31 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
FR2578423B1 (en) 1985-03-06 1988-12-30 Grimberg Georges GUAR GUM-BASED PHARMACEUTICAL COMPOSITION FOR THE PROTECTION OF THE OESO-GASTRO-DUODENAL MUCOSA
US4594248A (en) 1985-03-15 1986-06-10 Warner-Lambert Company CL-1577-B4 compound, its production and use
US4657757A (en) 1985-03-29 1987-04-14 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4695591A (en) 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
CA1279574C (en) 1985-04-17 1991-01-29 Jeffrey L. Finnan Process for lubricating water-soluble vitamin powders
EP0207638B1 (en) 1985-06-04 1990-12-19 Teijin Limited Sustained-release pharmaceutical preparation
FR2585246A1 (en) 1985-07-26 1987-01-30 Cortial PROCESS FOR OBTAINING SOLID PHARMACEUTICAL FORMS WITH PROLONGED RELEASE
GB8521350D0 (en) 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
GB8521494D0 (en) 1985-08-29 1985-10-02 Zyma Sa Controlled release tablet
US4710519A (en) 1985-09-30 1987-12-01 Basf Corporation Process for preparing spray dried acetaminophen powder and the powder prepared thereby
CA1259915A (en) 1985-10-09 1989-09-26 Sailen S. Mookerjea Means to reduce plasma cholesterol
IT1187750B (en) 1985-10-15 1987-12-23 Eurand Spa PROCEDURE FOR THE PREPARATION OF TABLETS, EVEN OF PROLONGED RELEASE, OF ISCSORBIDE-5-MONONITRATE STABILIZED AND FORMULATIONS SO OBTAINED
US4753801A (en) 1985-10-25 1988-06-28 Eli Lilly And Company Sustained release tablets
US4734285A (en) 1985-10-28 1988-03-29 The Dow Chemical Company Sustained release compositions
JPS62106019A (en) 1985-11-01 1987-05-16 Terumo Corp Anti-hyperlipemic agent
US4704285A (en) 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
DE3541428A1 (en) 1985-11-23 1987-05-27 Hoechst Ag NEW BASICALLY SUBSTITUTED PYRIDINE COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF, THE MEDICINAL PRODUCTS CONTAINING IT AND THEIR USE
US4696762A (en) 1985-12-06 1987-09-29 Zumbro Enterprises, Inc. Hydroxypropylmethylcellulose
IT1188212B (en) 1985-12-20 1988-01-07 Paolo Colombo SYSTEM FOR THE RELEASE SPEED OF ACTIVE SUBSTANCES
IE63321B1 (en) 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
US4837032A (en) 1986-02-04 1989-06-06 Farval Ag Theophylline sustained release tablet
IT1191674B (en) 1986-03-07 1988-03-23 Eurand Spa FORMULATIONS FOR THE PREPARATION OF PROLONGED-RELEASE DRUGS SUITABLE FOR ORAL ADMINISTRATION
US4775535A (en) 1986-04-04 1988-10-04 Hans Lowey Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
US4855143A (en) 1986-04-04 1989-08-08 Hans Lowey Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
SE8601624D0 (en) 1986-04-11 1986-04-11 Haessle Ab NEW PHARMACEUTICAL PREPARATIONS
US4756911A (en) 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
DE3614019A1 (en) 1986-04-25 1987-11-05 Degussa METHOD FOR PRODUCING HIGH PURITY CRYSTAL CRYSTALLINE NICOTINIC ACID
US4795642A (en) 1986-05-01 1989-01-03 Pharmacaps, Inc. Gelatin-encapsulated controlled-release composition
US4708834A (en) 1986-05-01 1987-11-24 Pharmacaps, Inc. Preparation of gelatin-encapsulated controlled release composition
US4752479A (en) 1986-05-27 1988-06-21 Ciba-Geigy Corporaton Multi vitamin and mineral dietary supplement with controlled release bioavailable iron
GB8613688D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4946870A (en) 1986-06-06 1990-08-07 Union Carbide Chemicals And Plastics Company Inc. Delivery systems for pharmaceutical or therapeutic actives
US4824672A (en) 1986-06-06 1989-04-25 Hauser-Kuhrts, Inc. Method and composition for reducing serum cholesterol
IT1200178B (en) 1986-07-23 1989-01-05 Alfa Farmaceutici Spa GALENIC FORMULATIONS WITH SCHEDULED SALE CONTAINING DRUGS WITH ANTI-FLOGISTIC ACTIVITY
CH668187A5 (en) 1986-08-07 1988-12-15 Ciba Geigy Ag THERAPEUTIC SYSTEM WITH SYSTEMIC EFFECT.
US5032608A (en) 1986-09-10 1991-07-16 Dudrick Stanley J Method and substrate composition for treating atherosclerosis
US4814354A (en) 1986-09-26 1989-03-21 Warner-Lambert Company Lipid regulating agents
US4851233A (en) 1986-10-06 1989-07-25 Warner-Lambert Company Sustained release formulations
GB8628359D0 (en) 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
US4824677A (en) 1986-12-18 1989-04-25 The Unjohn Company Grooved tablet for fractional dosing of sustained release medication
ES2039287T3 (en) 1987-01-14 1993-09-16 Ciba-Geigy Ag PROCEDURE FOR OBTAINING A PERORAL THERAPEUTIC SYSTEM FOR HARDLY SOLUBLE ACTIVE PRODUCTS.
US4744907A (en) 1987-01-16 1988-05-17 Interferon Sciences, Inc. Blood cell separation
JP2547995B2 (en) 1987-01-26 1996-10-30 昭和電工株式会社 Granules for ruminants and method for producing the same
US5015479A (en) 1987-02-02 1991-05-14 Seamus Mulligan Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
US4851232A (en) 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
US5110940A (en) 1987-02-25 1992-05-05 Bristol-Myers Company Antihypercholesterolemic tetrazole compounds
US4915952A (en) 1987-02-27 1990-04-10 Alza Corporation Composition comprising drug, HPC, HPMC and PEO
US4968508A (en) 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US4789549A (en) 1987-03-09 1988-12-06 Warner-Lambert Company Sustained release dosage forms
US4950689A (en) 1987-03-31 1990-08-21 Yang Robert K Pectin delivery system
US4786503A (en) 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
GB8710965D0 (en) 1987-05-08 1987-06-10 Smith Kline French Lab Pharmaceutical compositions
KR960011236B1 (en) 1987-05-08 1996-08-21 스미스 클라인 앤드 프렌취 라보라토리스 리미티드 Pharmaceutical Compositions and Solid Formulations
DE3720757A1 (en) 1987-06-24 1989-01-05 Bayer Ag DHP COAT TABLET
US4759923A (en) 1987-06-25 1988-07-26 Hercules Incorporated Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
DE3721721C1 (en) 1987-07-01 1988-06-09 Hoechst Ag Process for coating granules
FR2618073B1 (en) 1987-07-16 1990-09-07 Pf Medicament HYDROPHILIC MATRIX-TYPE TABLETS BASED ON SALBUTAMOL AND THEIR PREPARATION METHOD
US4792452A (en) 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US4795644A (en) 1987-08-03 1989-01-03 Merck & Co., Inc. Device for pH independent release of drugs through the Donnan-like influence of charged insoluble resins
US4814183A (en) 1987-08-31 1989-03-21 Merck & Co., Inc. Device for the controlled release of drugs with Donnan-like modulation by charged insoluble resins
US4994276A (en) 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
IL87710A (en) 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
IE60311B1 (en) 1987-09-24 1994-06-29 American Home Prod Sustained release etodolac
SE8703881D0 (en) 1987-10-08 1987-10-08 Haessle Ab NEW PHARMACEUTICAL PREPARATION
US5022774A (en) 1987-10-09 1991-06-11 Kotobuki & Co., Ltd. Writing tool with eraser dispenser
US4965252A (en) 1988-06-28 1990-10-23 Hauser-Kuhrts, Inc. Cholesterol-lowering combination compositions of guar gum and niacin
US4911917A (en) 1988-06-28 1990-03-27 Hauser-Kuhrts, Inc. Cholesterol-lowering combination comopsitions of magnesium salt and niacin
US5023245A (en) 1987-11-10 1991-06-11 Hauser-Kuhrts, Inc. Improved niacin formulation
US4946963A (en) 1987-11-13 1990-08-07 The University Of North Carolina At Chapel Hill Compounds for the control of hyperlipidemia using N-substituted isoxazolidine-3,5-diones
US5211958A (en) 1987-11-30 1993-05-18 Gist-Brocades, N.V. Pharmaceutical composition and process for its preparation
US4983398A (en) 1987-12-21 1991-01-08 Forest Laboratories, Inc. Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
US5116610A (en) 1987-12-29 1992-05-26 The Procter & Gamble Company Compositions for treating hypercholesterolemia
US4994267A (en) 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
US5178854A (en) 1988-03-24 1993-01-12 Taisho Pharmaceutical Co., Ltd. Cholesterol-lowering agents
US5030653A (en) 1988-03-30 1991-07-09 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic compounds and compositions
US5049696A (en) 1988-04-11 1991-09-17 Merck & Co., Inc. Antihypercholesterolemic compounds
DE3812402A1 (en) 1988-04-14 1989-10-26 Basf Ag METHOD FOR THE PRODUCTION OF WATER-SOLUBLE COPOLYMERISATS BASED ON MONOETHYLENICALLY UNSATURATED CARBONIC ACIDS AND THE USE THEREOF
US5096714A (en) 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
US5034528A (en) 1988-07-27 1991-07-23 North Carolina Central University Compositions for the control of hyperlipidemia
US4866058A (en) 1988-07-27 1989-09-12 Izydore Robert A Method for control of hyperlipidemia
US5196440A (en) 1988-07-29 1993-03-23 Zambon Group S.P.A. Compounds active as inhibitors of the cholesterol biosynthesis
US5011947A (en) 1988-08-25 1991-04-30 Bristol-Myers Antihypercholesterolemic alkylene compounds
US5169639A (en) 1988-09-19 1992-12-08 Edward Mendell Co., Inc. Controlled release verapamil tablets
US4999380A (en) 1988-10-18 1991-03-12 Nestec S.A. Treatment of lipoprotein disorders associated with cholesterol metabolism
US5110817A (en) 1988-10-21 1992-05-05 Beyer Jr Karl H Method for controlling and/or lowering serum triglyceride and/or cholesterol levels in mammals
US4920123A (en) 1988-10-21 1990-04-24 Beyer Jr Karl H Method for controlling and/or lowering serum triglyceride and/or cholesterol levels in mammals
US4997658A (en) 1988-11-21 1991-03-05 Merck & Co., Inc. Method for enhancing the lowering of plasma cholesterol levels
US5260305A (en) 1988-12-12 1993-11-09 E. R. Squibb & Sons, Inc. Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
US5039341A (en) 1988-12-19 1991-08-13 The Dow Chemical Company Binder composition comprises a blend of a high viscosity and low viscosity hydroxypropyl methylcellulose ether, and a tape joint composition containing such binder
US4920115A (en) 1988-12-28 1990-04-24 Virginia Commonwealth University Method of lowering LDL cholesterol in blood
US4970081A (en) 1989-01-03 1990-11-13 Sterling Drug Inc. Controlled-release, low-dose aspirin formulation and method of treating vascular occlusive disease therewith
US5032406A (en) 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
JP2664238B2 (en) 1989-03-01 1997-10-15 日清製粉株式会社 Nicotinic acid or its ester derivatives
US4973468A (en) 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
US5126145A (en) 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US4990535A (en) 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5002774A (en) 1989-06-08 1991-03-26 Erbamont, Inc. Sustained release pharmaceutical tablet
US5010105A (en) 1989-06-09 1991-04-23 Merck & Co., Inc. Antihypercholesterolemic compounds
US5264226A (en) 1989-07-12 1993-11-23 Roquette Freres Process for preparing dairy products with a low content of sterols, particularly of cholesterol
US4970221A (en) * 1989-07-28 1990-11-13 E. R. Squibb & Sons, Inc. 3,5-dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
US5262165A (en) 1992-02-04 1993-11-16 Schering Corporation Transdermal nitroglycerin patch with penetration enhancers
DK469989D0 (en) 1989-09-22 1989-09-22 Bukh Meditec PHARMACEUTICAL PREPARATION
US5126348A (en) * 1989-09-26 1992-06-30 The University Of Colorado Foundation, Inc. Bioavailability enhancers
US5171570A (en) 1989-12-08 1992-12-15 Lotte Company Limited Substance having suppressing function for diseases relating to increase in cholesterol, and foods and drinks in which it is used
US5009895A (en) 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5190940A (en) 1990-09-14 1993-03-02 American Home Products Corporation Cholesterol ester hydrolase inhibitors
US5190970A (en) 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5130333A (en) 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
US5286736A (en) 1990-11-22 1994-02-15 Dr. Karl Thomae Gmbh Pyridyl compounds and pharmaceutical compositions containing these compounds
GB9100437D0 (en) 1991-01-09 1991-02-20 Glaxo Group Ltd Chemical compounds
US5145678A (en) 1991-01-22 1992-09-08 Dusko Gakic Method of reducing blood serum cholesterol
US5182298A (en) 1991-03-18 1993-01-26 Merck & Co., Inc. Cholesterol lowering agents
US5256689A (en) 1991-05-10 1993-10-26 Merck & Co., Inc. Cholesterol lowering compounds
US5169638A (en) 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
US5262435A (en) 1992-02-10 1993-11-16 Merck & Co., Inc. Cholesterol lowering compounds
US5167964A (en) 1992-02-14 1992-12-01 Warner-Lambert Company Semi-enteric drug delivery systems and methods for preparing same
US5258401A (en) 1992-07-10 1993-11-02 Merck & Co., Inc. Cholesterol lowering compounds
US5314697A (en) 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6818229B1 (en) * 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6746691B2 (en) * 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6406715B1 (en) * 1993-09-20 2002-06-18 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles
US6080428A (en) * 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
EP0643965B1 (en) 1993-09-20 2013-05-08 Abbott Laboratories Nicotinic acid compositions for treating hyperlipidemia
US6129930A (en) * 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US20080045573A1 (en) * 1993-09-20 2008-02-21 Bova David J Methods and Sustained Release Nicotinic Acid Compositions for Treating Hyperlipidemia
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
CA2218696A1 (en) * 1995-04-19 1996-10-24 L. Jackson Ii Roberts Compositions, kits and methods for administration of antilipemic and an ti-platelet aggregation drugs
US5773453A (en) * 1995-04-19 1998-06-30 Vanderbilt University Methods for administration of antilipemic drugs
US20030157153A1 (en) * 1997-03-06 2003-08-21 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6469035B1 (en) * 1997-07-31 2002-10-22 Eugenio A. Cefali Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
US20060171970A1 (en) * 2003-02-21 2006-08-03 Cardio Combos Llc Pharmaceutical formulation delivery system
CA2569776A1 (en) * 2006-02-17 2007-08-17 Kos Life Sciences, Inc. Low flush niacin formulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268181A (en) * 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100076033A1 (en) * 1993-09-20 2010-03-25 Eugenio Cefali Methods For Treating Hyperlipidemia with Intermediate Release Nicotinic Acid Compositions Having Unique Biopharmaceutical Characteristics
US20120035225A1 (en) * 1993-09-20 2012-02-09 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US20130005779A1 (en) * 1993-09-20 2013-01-03 Cefali Eugenio A Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics

Also Published As

Publication number Publication date
US20070224270A1 (en) 2007-09-27
US20070225341A1 (en) 2007-09-27
US20120157503A1 (en) 2012-06-21
US20090036500A1 (en) 2009-02-05
US6676967B1 (en) 2004-01-13
US20110245298A1 (en) 2011-10-06
US20110245300A1 (en) 2011-10-06
US20070225342A1 (en) 2007-09-27
US7998506B2 (en) 2011-08-16
US20070237819A1 (en) 2007-10-11
US20050118257A1 (en) 2005-06-02
US20090203748A1 (en) 2009-08-13
US20110003783A1 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
US20090186925A1 (en) Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US7011848B1 (en) Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US20110245299A1 (en) Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6818229B1 (en) Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6406715B1 (en) Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles
US6746691B2 (en) Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US20130005779A1 (en) Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US20110301207A1 (en) Methods and sustained release nicotinic acid compositions for treating hyperlipidemia
US20030157153A1 (en) Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
AU775967B2 (en) Starter kit containing nicotinic acid compositions
AU2005202310A1 (en) Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
CA2574987A1 (en) Nicotinic acid compositions for treating hyperlipidemia and related methods therefor

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载